MeSH tree: C05.116.900.853.625.800
Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation—called tyrosine kinase 2 and Janus kinase 1—and is being tested for the treatment of several immunological diseases. A phase IIb randomized ...
May 17, 2023
0
42
Alopecia areata (AA) is associated with a higher risk for inflammatory arthritis, according to a study published online April 28 in the Journal of the American Academy of Dermatology.
May 15, 2023
0
109
Most people have heard of osteoarthritis and rheumatoid arthritis. But for some, psoriatic arthritis is the new kid on the block. Here's what you need to know about psoriatic arthritis, including symptoms, types and treatments.
Apr 24, 2023
0
96
There are more than 100 types of arthritis and related conditions, and they affect at least 54 million adults and 300,000 children in the United States, according to the Arthritis Foundation.
Apr 20, 2023
0
252
Arthritis strikes millions of Americans, leaving them with aching, inflamed joints that make it hard to move around without pain.
Apr 17, 2023
0
79
A study by Swansea University has revealed how machine learning can help with the early detection of Ankylosing Spondylitis (AS) inflammatory arthritis and revolutionize how people are detected and diagnosed by their GPs.
Apr 5, 2023
0
63
Skin issues can have a serious impact on your health and well-being. For the 7.5 million Americans living with psoriasis, itch can be the most bothersome part of their condition because it can make it difficult to sleep and ...
Mar 23, 2023
0
109
Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promising" treatment for alcohol use disorder.
Feb 21, 2023
0
70
The typical person living with arthritis in the U.K. is 20% less likely to be employed than their equivalent without the condition, new research shows.
Jan 30, 2023
0
67
Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.
Jan 11, 2023
0
57
